218 related articles for article (PubMed ID: 15986076)
21. Therapeutic dose monitoring of mycophenolate mofetil in dermatologic diseases.
Sokumbi O; el-Azhary RA; Langman LJ
J Am Acad Dermatol; 2013 Jan; 68(1):36-40. PubMed ID: 22884445
[TBL] [Abstract][Full Text] [Related]
22. New immunosuppressive drugs in dermatology (mycophenolate mofetil, tacrolimus): unapproved uses, dosages, or indications.
Assmann T; Ruzicka T
Clin Dermatol; 2002; 20(5):505-14. PubMed ID: 12435521
[No Abstract] [Full Text] [Related]
23. New immunosuppressive agents in clinical use: mycophenolate mofetil and tacrolimus.
Hunt SA
Cardiol Rev; 2000; 8(3):180-4. PubMed ID: 11174892
[TBL] [Abstract][Full Text] [Related]
24. Molecular mechanisms of new immunosuppressants.
Halloran PF
Clin Transplant; 1996 Feb; 10(1 Pt 2):118-23. PubMed ID: 8680047
[TBL] [Abstract][Full Text] [Related]
25. The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors.
Sintchak MD; Nimmesgern E
Immunopharmacology; 2000 May; 47(2-3):163-84. PubMed ID: 10878288
[TBL] [Abstract][Full Text] [Related]
26. An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients.
Vannozzi F; Filipponi F; Di Paolo A; Danesi R; Urbani L; Bocci G; Catalano G; De Simone P; Mosca F; Del Tacca M
Transplant Proc; 2004 Nov; 36(9):2787-90. PubMed ID: 15621150
[TBL] [Abstract][Full Text] [Related]
27. [Efficiency of mycophenolate mofetil in the treatment of intermediate and posterior uveitis].
Greiner K; Varikkara M; Santiago C; Forrester JV
Ophthalmologe; 2002 Sep; 99(9):691-4. PubMed ID: 12219257
[TBL] [Abstract][Full Text] [Related]
28. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment.
Vethe NT; Mandla R; Line PD; Midtvedt K; Hartmann A; Bergan S
Scand J Clin Lab Invest; 2006; 66(1):31-44. PubMed ID: 16464785
[TBL] [Abstract][Full Text] [Related]
29. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients.
Weigel G; Griesmacher A; Zuckermann AO; Laufer G; Mueller MM
Clin Pharmacol Ther; 2001 Mar; 69(3):137-44. PubMed ID: 11240978
[TBL] [Abstract][Full Text] [Related]
30. Mechanism of action of mycophenolate mofetil.
Ransom JT
Ther Drug Monit; 1995 Dec; 17(6):681-4. PubMed ID: 8588241
[TBL] [Abstract][Full Text] [Related]
31. [Mycophenolate mofetil--a new immunosuppressive agent].
Bergan S; Albrechtsen D; Fauchald P
Tidsskr Nor Laegeforen; 1996 Aug; 116(20):2439-41. PubMed ID: 8928103
[TBL] [Abstract][Full Text] [Related]
32. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. European Mycophenolate Mofetil Cooperative Study Group.
Transplantation; 1999 Aug; 68(3):391-6. PubMed ID: 10459543
[TBL] [Abstract][Full Text] [Related]
33. Mycophenolate mofetil (MMF) in heart transplantation: rejection prevention and treatment.
Renlund DG; Gopinathan SK; Kfoury AG; Taylor DO
Clin Transplant; 1996 Feb; 10(1 Pt 2):136-9. PubMed ID: 8680051
[TBL] [Abstract][Full Text] [Related]
34. Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients.
Goldsmith D; Carrey EA; Edbury S; Smolenski RT; Jagodzinski P; Simmonds HA
Clin Sci (Lond); 2004 Jul; 107(1):63-8. PubMed ID: 14723604
[TBL] [Abstract][Full Text] [Related]
35. Mycophenolate mofetil treatment in dogs with serologically diagnosed acquired myasthenia gravis: 27 cases (1999-2008).
Dewey CW; Cerda-Gonzalez S; Fletcher DJ; Harb-Hauser MF; Levine JM; Badgley BL; Olby NJ; Shelton GD
J Am Vet Med Assoc; 2010 Mar; 236(6):664-8. PubMed ID: 20225980
[TBL] [Abstract][Full Text] [Related]
36. Mycophenolate mofetil in systemic lupus erythematosus: results from a retrospective study in a large monocentric cohort and review of the literature.
Conti F; Ceccarelli F; Perricone C; Massaro L; Cipriano E; Pacucci VA; Truglia S; Miranda F; Morello F; Alessandri C; Spinelli FR; Valesini G
Immunol Res; 2014 Dec; 60(2-3):270-6. PubMed ID: 25468307
[TBL] [Abstract][Full Text] [Related]
37. Mizoribine and mycophenolate mofetil.
Ishikawa H
Curr Med Chem; 1999 Jul; 6(7):575-97. PubMed ID: 10390602
[TBL] [Abstract][Full Text] [Related]
38. RS-61443: successful rescue therapy in refractory renal rejection.
Sollinger HW; Deierhoi MH; Kauffman RS; Diethelm AG; Belzer FO
Transpl Int; 1992; 5 Suppl 1():S448-9. PubMed ID: 14621842
[TBL] [Abstract][Full Text] [Related]
39. Mycophenolate mofetil.
Sievers TM; Rossi SJ; Ghobrial RM; Arriola E; Nishimura P; Kawano M; Holt CD
Pharmacotherapy; 1997; 17(6):1178-97. PubMed ID: 9399601
[TBL] [Abstract][Full Text] [Related]
40. Mycophenolate mofetil, Crohn's disease, measles?
Altschuler EL
Am J Gastroenterol; 2000 Feb; 95(2):550-1. PubMed ID: 10685769
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
